Start | Browse by Program | Author Index

Drug Discovery and Development

P89
A Significant Bioactivation Pathway Common to 2-(Alkylthio)-1, 3, 4-Thiadiazoles
Yanou Yang, Bristol-Myers Squibb Co; Jonathan Josephs, Bristol-Myers Squibb Co; W. Griff Humphreys, Bristol-Myers Squibb Company; Yue-Zhong Shu, Bristol-Myers Squibb
P90
Bioavailability and In-Vivo Efficacy of Praziquantel-Polyvinylpyrrolidone Solid Dispersion in S. mansoni-Infected Mice
Sayed Seif el-Din, Theodor Bilharz Research Institute; Naglaa El-Lakkany, Theodor Bilharz Research Institute; Lamia Heikal, Faculty of Pharmacy, Alexandria University.
P91
Brain Microdialysis of Pomalidomide in Rats
Mehran Moghaddam, Celgene Corporation; Jason Katz, Celgene Corporation; Yang Tang, Celgene Corporation
P92
Cardiomyocytes from Stem Cells: Towards "Disease in a Dish"
John R. Cashman, Human BioMolecular Research Institute; Marion Lanier, Human BioMolecular Research Institute; Dennis Schade, Human BioMolecular Research Institute; Erik Willems, Sanford Burnham Research Institute; Masa Tsuda, Sanford Burnham Research Institute; Mark Mercola, Sanford Burnham Research Institute
P93
Comparison of Various Nonclinical In Vivo/In Vitro Models to Assess CNS Penetration of TAK-285, a Novel HER2/EGFR Inhibitor
Jing-Tao Wu, Millennium Pharmaceuticals, Inc.; Justin Gordon, Millennium Pharmaceuticals, Inc.; Mingxiang Liao, Millennium Pharmaceuticals, Inc.; Qing Zhu, Millennium Pharmaceuticals, Inc.; Alex Bulychev, Millennium Pharmaceuticals, Inc.; Susan Chen, Millennium Pharmaceuticals, Inc.; Karthik Venkatakrishnan, Millennium Pharmaceuticals, Inc.; Cindy Xia, Millennium Pharmaceuticals, Inc.
P94
Derisking Idiosyncratic Toxicity Concerns with a Covalent Modifying Drug: Retrospective analysis with the pan-ErbB Receptor Tyrosine Kinase Inhibitor and Clinical Candidate (CI-1033, Canertinib)
Jonathan N. Bauman, Pfizer Global Reseach and Development; Xin Yang, Pfizer Global Reseach and Development; Raman Sharma, Pfizer Global Reseach and Development; Amit S. Kalgutkar, Pfizer Global Reseach and Development
P95
Effect of Pharmaceutical Vehicles on the Brain Penetration
Nageswararao Muddana, Suven Life Sciences Ltd; Vishwottam Kandikere, Suven Life Sciences Ltd; Gopinadh Bhyrapuneni, Suven Life Sciences Ltd; Ramoji Kosuru, Suven Life Sciences Ltd; Ranjit kumar Ponnamaneni, Suven Life Sciences Ltd; Shantaveer Irappanavar, Suven Life Sciences Ltd; Arun Kumar Manoharan, Suven Life Sciences Ltd; Ramakrishna Nirogi, Suven Life Sciences Ltd
P96
Evaluation of Cellular Uptake of Three Paclitaxel Formulations in Cancer Cells
Siu Kwan Wo, The Chinese University of Hong Kong; Chen Rui Li, The Chinese University of Hong Kong; Zhong Zuo, The Chinese University of Hong Kong
P98
Improved Bioanalysis and Pharmacokinetics by Integrating Radiolabeled Metabolism Data from a Human Clinical ADME Study of [14C]2-PAP Prodrug
Gregory K. Poch, Worldwide Clinical Trials Drug Development Solutions; Steve Unger, Worldwide Clinical Trials Drug Development Solutions; Nadia Martinez, Worldwide Clinical Trials Drug Development Solutions; Selynda Garza, Worldwide Clinical Trials Drug Development Solutions; Edward Wells, Worldwide Clinical Trials Drug Development Solutions; Suma Krishnan, Pinnacle Pharmaceuticals Inc; Schuyler Vinzant, Worldwide Clinical Trials Drug Development Solutions
P99
Linear Ion Trap vs. High Resolution Accurate Mass QqTOF MS: Which Provides More Useful Data in a Drug Discovery Program?
James A. Ferguson, AB SCIEX; Richard P. Schneider, Pfizer Global R&D; Veronica A. Zelesky, Pfizer Global R&D; Brendon Kapinos, Pfizer Global R&D; Alfin Vaz, Pfizer Global R&D
P100
Meropenem Prodrugs for the Treatment of Tuberculosis
Aaron M. Teitelbaum, University of Minnesota; Courtney C. Aldrich, University of Minnesota; Rory P. Remmel, University of Minnesota
P101
Metabolism and Excretion of a Potent p38 Mitogen-Activated Protein Kinase Inhibitor N-cyclopropyl-3-(1-(2,6-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-5-yl)-4-methylbenzamide
Jinyan Lin, Amgen Inc.; Dean Hickman, Amgen Inc.; Gary Skiles, Amgen Inc.; Faye Hsieh, Amgen Inc.
P102
Novel Synthetic Omega-3 Monounsaturated Fatty Acids Inhibit the Proliferative Activity of Breast Cancer Cells that Over-express COX-2
Pei H. Cui, The University of Sydney; Tristan Rawling, The University of Sydney; Kirsi Bourget, The University of Sydney; Nenad Petrovic, University of South Australia; Michael Murray, The University of Sydney
P103
Preclinical Assessment Of The Absorption, Distribution, Metabolism And Excretion Of HMPL-013, A Novel Potent And Specific VEGFR Inhibitor
Yi Gu, Hutchison MediPharma Limited; Jian Wang, Hutchison MediPharma Limited; Hongcan Ren, Hutchison MediPharma Limited; Li Zhang, Hutchison MediPharma Limited; Lixia Guo, Hutchison MediPharma Limited; Ke Li, Hutchison MediPharma Limited; Weihan Zhang, Hutchison MediPharma Limited; Weiguo Su, Hutchison MediPharma Limited; Yang Sai, Hutchison MediPharma Limited
P104
Reactive Metabolite Screening in Early ADME using Rapid High Resolution Accurate Mass Technology
James A. Ferguson, AB SCIEX; Richard P. Schneider, Pfizer Global R&D; Veronica A. Zelesky, Pfizer Global R&D; Hui Zhang, Pfizer Global R&D
P105
Screening newly synthesized curcumin analogues with improved pharmacokinetic properties by in vitro Caco-2 model and in vivo bioavailability studies
Deng Ying, Southern Medical Univerity; Hu Jingqing, Sun Yat-sen University; Bi Huichang, Sun Yat-sen University; Jin Jing, Sun Yat-sen University; Cai Yike, Sun Yat-sen University; Bu Xianzhang, Sun Yat-sen University; Huang Min, Sun Yat-sen University
P106
Species Differences in the Oral Bioavailability of a Novel MET Kinase Inhibitor
Bianca M. Liederer, Genentech Inc.; Leonid M. Berezhkovskiy, Genentech Inc.; Vikki Dinkel, Array BioPharma Inc.; Emile G. Plise, Genentech Inc.; Susan Wong, Genentech Inc.; Dan Sutherlin, Genentech Inc.
P107
Stereoselectivity: Assessment of In Vitro and In Vivo Preclinical Properties including Toxicity of Carboxamide Enantiomers
Bianca M. Liederer, Genentech Inc.; Eric Harstad, Genentech Inc.; Leonid M. Berezhkovskiy, Genentech Inc.; Emile G. Plise, Genentech Inc.; Dan Sutherlin, Genentech Inc.; Xingrong Liu, Genentech Inc.
P109
The Pharmacokinetics And Metabolism Of HMPL012, A Novel Potent Inhibitor Targeting Multiple Kinases
Jian Wang, Hutchison MediPharma Limited; Yi Gu, Hutchison MediPharma Limited; Weifang Xue, Hutchison MediPharma Limited; Li Zhang, Hutchison MediPharma Limited; Li Ke, Hutchison MediPharma Limited; Zheyi Hu, Hutchison MediPharma Limited; Weihan Zhang, Hutchison MediPharma Limited; Weiguo Su, Hutchison MediPharma Limited; Yang Sai, Hutchison MediPharma Limited
P110
The Role of the Liver and Kidney in the Pharmacokinetics of Subcutaneously Administered Teriparatide Acetate in Rats
Aki Sakurai, Asahi Kasei Pharma Corporation; Masashi Serada, Asahi Kasei Pharma Corporation; Masayo Igarashi, Asahi Kasei Pharma Corporation; Koichi Mitsugi, Sekisui Medical Co., Ltd.; Toshie Takano, Sekisui Medical Co., Ltd.; Koichi Shibusawa, Sekisui Medical Co., Ltd.; Terutomo Kohira, Asahi Kasei Pharma Corporation
P111
The use of UV-MS correlation for the quantification of plasma metabolites on a dual-cell linear ion trap
Tim Stratton, Thermo Fisher Scientific; August Specht, Thermo Fisher Scientific; Julie Horner, Thermo Fisher Scientific; Yingying Huang, Thermo Fisher Scientific
See more of: Poster and Oral Presentations
<< Previous Session | Next Session >>